Dare Bioscience IncDARE
Price$0.85

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $1.4M+13,860.9% YoYTTM through 30 Jun 2026
Net Income -$11MTTM through 30 Jun 2026
Free Cash Flow -$11.8MTTM through 30 Jun 2026

Margins

Current
Gross Margin-59.0%
EBITDA Margin-657.3%
Operating Margin-1,967.1%
Net Margin-804.4%

Returns

-43.2%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio1.02x
Net Debt-$18.5Mnet cash position
Cash & Equivalents$12.6M

Quality Metrics

Altman Z-Score-13.34
Piotroski F-Score1 / 9
FCF Margin-860.6%
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'21'22'23'24'25
FY2025: $1M
Diluted EPS-$0.66TTM
'17'20'21'22'23'24'25
FY2025: $-1.20

Dividend

No dividend

Capital Allocation

Capex Intensity33.8%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.